| Date | Time | Source | Headline | Symbol | Company |
| 05/17/2024 | 3:00PM | iHub Newswire | FeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements | | |
| 08/18/2023 | 4:21AM | PR Newswire (US) | FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy | LSE:0A5R | Calliditas Therapeutics Ab |
| 08/18/2023 | 4:17AM | PR Newswire (US) | FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy | LSE:0A5R | Calliditas Therapeutics Ab |
| 08/17/2023 | 1:29AM | PR Newswire (US) | Interim Report Q2, 2023: Calliditas Therapeutics | LSE:0A5R | Calliditas Therapeutics Ab |
| 08/15/2023 | 4:52AM | PR Newswire (US) | Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet | LSE:0A5R | Calliditas Therapeutics Ab |
| 08/15/2023 | 4:50AM | PR Newswire (US) | Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet | LSE:0A5R | Calliditas Therapeutics Ab |
| 07/13/2023 | 2:20AM | PR Newswire (US) | Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib | LSE:0A5R | Calliditas Therapeutics Ab |
| 07/13/2023 | 2:17AM | PR Newswire (US) | Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib | LSE:0A5R | Calliditas Therapeutics Ab |
| 06/21/2023 | 4:12AM | PR Newswire (US) | Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® | LSE:0A5R | Calliditas Therapeutics Ab |
| 06/21/2023 | 4:10AM | PR Newswire (US) | Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® | LSE:0A5R | Calliditas Therapeutics Ab |
| 05/30/2023 | 10:18AM | PR Newswire (US) | Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) | LSE:0A5R | Calliditas Therapeutics Ab |
| 05/30/2023 | 10:16AM | PR Newswire (US) | Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) | LSE:0A5R | Calliditas Therapeutics Ab |
| 05/16/2023 | 1:17AM | PR Newswire (US) | Calliditas Therapeutics: Interim Report Q1, 2023 | LSE:0A5R | Calliditas Therapeutics Ab |
| 05/16/2023 | 1:14AM | PR Newswire (US) | Calliditas Therapeutics: Interim Report Q1, 2023 | LSE:0A5R | Calliditas Therapeutics Ab |
| 05/05/2023 | 9:01AM | PR Newswire (US) | Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 | LSE:0A5R | Calliditas Therapeutics Ab |
| 05/05/2023 | 9:00AM | PR Newswire (US) | Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 | LSE:0A5R | Calliditas Therapeutics Ab |
| 04/28/2023 | 4:54AM | PR Newswire (US) | Notice of annual general meeting of Calliditas Therapeutics AB (publ) | LSE:0A5R | Calliditas Therapeutics Ab |
| 04/28/2023 | 4:51AM | PR Newswire (US) | Notice of annual general meeting of Calliditas Therapeutics AB (publ) | LSE:0A5R | Calliditas Therapeutics Ab |
| 04/26/2023 | 10:40PM | PR Newswire (US) | Calliditas Therapeutics' 2022 Annual Report Published | LSE:0A5R | Calliditas Therapeutics Ab |
| 04/26/2023 | 6:15PM | PR Newswire (US) | Calliditas Therapeutics' 2022 Annual Report Published | LSE:0A5R | Calliditas Therapeutics Ab |
| 03/31/2023 | 11:24AM | PR Newswire (US) | Calliditas to participate in upcoming investor conferences | LSE:0A5R | Calliditas Therapeutics Ab |
| 03/31/2023 | 11:20AM | PR Newswire (US) | Calliditas to participate in upcoming investor conferences | LSE:0A5R | Calliditas Therapeutics Ab |
| 03/12/2023 | 11:15PM | PR Newswire (US) | Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy | LSE:0A5R | Calliditas Therapeutics Ab |
| 03/12/2023 | 11:06PM | PR Newswire (US) | Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy | LSE:0A5R | Calliditas Therapeutics Ab |
| 02/23/2023 | 1:41AM | PR Newswire (US) | Calliditas - Year-End Report, 2022 | LSE:0A5R | Calliditas Therapeutics Ab |
| 02/23/2023 | 1:34AM | PR Newswire (US) | Calliditas - Year-End Report, 2022 | LSE:0A5R | Calliditas Therapeutics Ab |
| 02/02/2023 | 3:46AM | PR Newswire (US) | Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy | LSE:0A5R | Calliditas Therapeutics Ab |
| 02/02/2023 | 3:44AM | PR Newswire (US) | Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy | LSE:0A5R | Calliditas Therapeutics Ab |
| 01/31/2023 | 2:22AM | PR Newswire (US) | Number of shares and votes in Calliditas Therapeutics | LSE:0A5R | Calliditas Therapeutics Ab |
| 12/30/2022 | 3:03AM | PR Newswire (US) | China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy | LSE:0A5R | Calliditas Therapeutics Ab |